Human embryonal carcinoma tumor antigen, Gp200/GCTM-2, is podocalyxin.

Biochem Biophys Res Commun

Division of Urology, Urological Research Laboratory, Beth Israel Deaconess Medical Center, Dana 838, 330 Brookline Ave., Boston, MA 02115, USA.

Published: January 2003

We previously characterized a peanut agglutinin-binding tumor antigen, gp200, a surface membrane glycoprotein expressed on human embryonal carcinoma, a malignant stem cell of testicular tumors. Gp200 is remarkably similar to another embryonal carcinoma antigen, GCTM-2, a cell differentiation marker that is also detected in blood of testis cancer patients, yet neither molecular identity is known. We now report the identity of gp200 as podocalyxin. Protein sequence results of gp200 peptides match with podocalyxin sequence. Furthermore, two distinct monoclonal antibodies, specific for podocalyxin, react positively with gp200. Therefore, gp200 is a testicular tumor form of podocalyxin, a surface membrane glycoprotein that was originally discovered as a scaffolding extracellular matrix protein of kidney podocyte cells. Podocalyxin is also expressed on subsets of hematopoietic cells where it has a putative function as a cell adhesion protein. This is the first report of podocalyxin expression on malignant cells.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0006-291x(02)02844-9DOI Listing

Publication Analysis

Top Keywords

embryonal carcinoma
12
human embryonal
8
tumor antigen
8
surface membrane
8
membrane glycoprotein
8
podocalyxin
7
gp200
6
carcinoma tumor
4
antigen gp200/gctm-2
4
gp200/gctm-2 podocalyxin
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!